ACG Updates Guidance on Crohn's Disease Management

The American College of Gastroenterology (ACG) has issued updated guidance on the management of Crohn's disease (CD) that reflects the surge in development of therapeutic options available since 2018, when the last guideline was published.
These newer treatment options include interleukin-23 (IL-23) blockers risankizumab, mirikizumab, and guselkumab; the anti-IL-12/23 agent ustekinumab; the JAK inhibitor upadacitinib; and the anti-integrin vedolizumab.
The intent of the guideline is to suggest 'preferable approaches' to CD management established through 'interpretation and collation of scientifically valid research, derived from extensive review of published literature,' said the writing group, led by Gary Lichtenstein, MD, director, Inflammatory Bowel Disease Center, Hospital of the University of Pennsylvania, Philadelphia.
When exercising clinical judgment, the authors advise healthcare providers to 'incorporate this guideline along with patient's needs, desires, and their values to care for patients fully and appropriately with CD.'
The guideline is intended to be 'flexible, not necessarily indicating the only acceptable approach,' and shared decision-making with the patient is advised, they stressed.
The 40-page guideline was published online earlier this month in American Journal of Gastroenterology, along with a one-page visual highlights summary .
From Diagnosis to Surgery
The incidence of CD has steadily increased over the past several decades, and both the diagnosis and treatment of patients with CD has evolved since 2018.
Table 1 of the guideline outlines all 35 recommendations for management of CD, which span diagnosis, endoscopy, medical management (broken down by mild-to-moderately severe disease with a lower or higher risk for disease progression), fistulizing CD, when to refer to surgery, and postoperative care (according to low and high risk for postoperative recurrence).
Table 2 of the guideline offers 59 'key concepts' covering clinical features, natural history, intestinal malignancy, diagnosis, disease modifiers, and medical and surgery management.
In making a diagnosis, it's important to consider clinical presentation as well as endoscopic, radiologic, histologic, and pathologic findings, the authors said.
They advise using fecal calprotectin (cutoff > 50-100 ug/g) to differentiate inflammatory from noninflammatory disease of the colon.
Routine endoscopic surveillance for colorectal cancer in patients with Crohn's colitis is also recommended.
Medical Treatment
'Medical treatment of CD is usually categorized into induction and maintenance therapy,' the authors wrote. Treatment regimens are usually chosen with 'a goal to achieve clinical and biomarker response within 12 weeks of treatment initiation followed by durable steroid-free control of disease activity including both clinical and endoscopic remission.' However, objective outcomes like endoscopic improvements have only recently been added to clinical trials, they noted.
The authors stressed that early initiation of advanced therapy is 'key' for optimal outcomes and that failure of conventional therapy before initiation of advanced therapy is not required.
For mild to moderately severe disease (with a lower risk for progression), oral mesalamine is not recommended for induction or maintenance; ileal release budesonide is recommended for induction but not maintenance; and sulfasalazine should be considered only for those with symptomatic mild colonic CD.
For moderate to severe CD (with a higher risk for progression) there are 17 recommendations, including:
Oral corticosteroids are recommended for short-term induction of remission but not maintenance.
Azathioprine and 6-mercaptopurine are not recommended for induction of remission but are recommended for maintenance of remission, with thiopurine methyltransferase testing done before initiation. However, given the adverse effect profile of thiopurine monotherapy, newer safer agents for maintenance should be considered.
Methotrexate for maintenance of steroid-free remission is suggested.
Anti-TNF agents (IV infliximab; SC adalimumab or certolizumab pegol) are recommended for induction and maintenance; SC infliximab for maintenance only; TB and hepatitis B status should be checked before treatment.
Vedolizumab, ustekinumab, upadacitinib, guselkumab, mirikizumab, and risankizumab are all options for induction and maintenance.
For fistulizing CD, infliximab, adalimumab, antibiotics, upadacitinib, vedolizumab or ustekinumab are recommended options for induction of remission.
Referral to Surgery
In terms of when to refer to surgery, patients with an intra-abdominal abscess > 2 cm should be treated with drainage and antibiotics. Patients with symptomatic fibrostenotic strictures or abdominal abscesses should be considered for surgery, the authors advised.
In patients with surgically induced remission, colonoscopy 6-12 months after surgery is recommended to assess for early recurrent CD.
Patients with a low post-op risk of recurrence can be observed. Patients with a high risk of post-op recurrence should consider starting advanced therapy shortly after resection with an anti-TNF agent or vedolizumab. High-risk patients include active smokers, those with penetrating disease and prior CD resections.
The guidance also emphasizes the importance of addressing disease modifiers including NSAID use, cigarette smoking, diet, and management of stress, depression, and anxiety.

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Vogue

28 minutes ago

• Vogue

EMDR: The Therapy Treatment That Miley Cyrus Says Saved Her Life

Anxiety can hinder so much of everyday life, but there are many helpful and safe ways to cope. For Miley Cyrus, she credits a specific type of therapy that helped her with stage fright and what she says also saved her life: EMDR. 'It's so weird because it's like watching a movie in your mind, but it's different than dreaming. You're kind of more in yourself, but still in another place of consciousness that's kind of hard to describe unless you've been in that hypnotic state,' the 32-year-old singer recently said in an interview with The New York Times. EMDR, more formally known as Eye Movement Desensitization and Reprocessing, is a psychotherapy technique that treats trauma-related stress and other mental health issues such as depression, anxiety, panic, grief, loss, and substance disorders. Developed by psychologist Francine Shapiro, PhD, in 1987, it has since been used to help adults (and even children). Cyrus goes on to explain in the interview that her therapist encouraged her to explore different points in her life that matched the anxiety she feels when she would go sing on stage. After finding herself on a mountaintop in a place where she experienced a lot of trauma, she was surrounded by nature and people—her grandma, her mom, her current boyfriend, her as a little child, and even her dog—who have brought her peace and love. When they all grabbed her hand to play Ring Around the Rosie, she came out of that vision feeling renewed. 'I've never had stage fright again,' she says. How does it work? EMDR involves reprocessing traumatic memories or stressful events using bilateral stimulation. Elizabeth Ochoa, PhD, chief psychologist at Mount Sinai-Behavioral Health Center, explains that you'll be asked to recall an emotion, an image, or words that are linked to that traumatic event while a form of bilateral stimulation is being administered by a clinician. The stimulation can include rapid eye movements, during which a person tracks the movements of a finger, ball, or some sort of stimulus with their eyes, tapping, or auditory cues. The goal, Ochoa says, is to reduce distress related to that painful memory. Who is it for? Ochao says that EMDR is perfect for those who are experiencing depression, anxiety, panic, or other emotional distress whenever a traumatic memory is triggered. If this is something that happens frequently enough over a long period of time and it starts to hinder how you live out your day to day life, she says this might be a treatment to consider. The benefits of EMDR Studies show that those who use EMDR can reap the same benefits as those who use years of psychotherapy, just in a shorter amount of time. The idea is that EMDR can help the mind recover from psychological trauma by removing mental blocks that stop the healing, similar to how the body recovers from physical trauma. 'The brain's information processing system naturally moves toward mental health. If the system is blocked or imbalanced by the impact of a disturbing event, the emotional wound festers and can cause intense suffering. Once the block is removed, healing resumes,' writes the EMDR Institute on its site. 'Using the detailed protocols and procedures learned in EMDR training sessions, clinicians help clients activate their natural healing processes.' The downsides of EMDR EMDR can be quite triggering at first. Ochao says that uncomfortable feelings or distressing thoughts, feelings, and even dreams will emerge as you're reprocessing these traumatic events. Those who are not ready to face those painful feelings may want to look for a gentler treatment option. EMDR is not for those who have personality disorders, diagnosed mental illnesses, or severe psychiatric disorders. She adds that this treatment is not suitable for ongoing trauma that is currently happening in your present life. 'In a general sense, for EMDR to be safely utilized, the patient needs to have sufficient emotional coping skills, distress tolerance, and stability to manage the emotional distress that will emerge during treatment safely,' she says. What to Expect During a Session There are eight phases in a single EMDR session. Ochao explains that the initial phase will focus on identifying the memory that is causing all the trauma. The following phase will try to desensitize that memory, using the same bilateral stimulation techniques. Once that memory is neutralized, she says the focus will shift to instilling positive beliefs. The EMDR Institute breaks it down even further like this:

Yahoo

28 minutes ago

• Yahoo

Health insurers vow to speed approval of medical care

UnitedHealthcare , Kaiser Permanente and other major U.S. health insurers say they want to make it faster and easier for patients to obtain care. Health Insurance Plans (AHIP), a trade association that represents the health insurance industry, announced Monday that some of its biggest members are taking steps to streamline "prior authorization" — industry jargon for the process by which health care providers obtain approval from patients' insurance carriers to deliver care. Prior authorization requests can be time-consuming for doctors, resulting in frustrating delays for patients in obtaining essential medical care. According to a survey from the American Medical Medical Association, physicians' offices spend an average of 12 hours per week seeking approval for services from insurers, administrative hurdles that critics say takes time away from providing care. As part of the new agreement, participating insurers have committed to a series of steps they say will speed up the sluggish process. That includes creating a standardized system for submitting prior authorization online, reducing the amount of claims subject to prior authorization and ramping up real-time responses to requests. Such changes are scheduled to take effect in 2026 and 2027. "The health care system remains fragmented and burdened by outdated manual processes, resulting in frustration for patients and providers alike," AHIP CEO Mike Tuffin said in a statement. "Health plans are making voluntary commitments to deliver a more seamless patient experience and enable providers to focus on patient care, while also helping to modernize the system." Shawn Martin, CEO of the American Academy of Family Physicians, said in a statement that the insurance industry initiative is a "step in the right direction," but that the real test will be the impact it has on the experiences of patients and physicians. Dozens of insurers signed onto the commitment, including a number of state Blue Cross and Blue Shield plans and some Medicare and Medicaid plans. In all, AHIP says the joint effort to improve prior authorization could benefit more than 250 million Americans. The signatories include: AmeriHealth Caritas Arkansas Blue Cross and Blue ShieldBlue Cross of IdahoBlue Cross Blue Shield of AlabamaBlue Cross Blue Shield of ArizonaBlue Cross and Blue Shield of HawaiiBlue Cross and Blue Shield of Kansas Blue Cross and Blue Shield of Kansas CityBlue Cross and Blue Shield of LouisianaBlue Cross Blue Shield of MassachusettsBlue Cross Blue Shield of MichiganBlue Cross and Blue Shield of MinnesotaBlue Cross and Blue Shield of NebraskaBlue Cross and Blue Shield of North CarolinaBlue Cross Blue Shield of North DakotaBlue Cross & Blue Shield of Rhode IslandBlue Cross Blue Shield of South CarolinaBlueCross BlueShield of TennesseeBlue Cross Blue Shield of WyomingBlue Shield of CaliforniaCapital Blue CrossCapital District Physicians' Health Plan, Inc. (CDPHP)CareFirst BlueCross BlueShieldCenteneThe Cigna GroupCVS Health AetnaElevance HealthExcellus Blue Cross Blue ShieldGeisinger Health PlanGuideWell Mutual Holding CorporationHealth Care Service CorporationHealthfirst (New York)Highmark Blue Cross Blue Shield of New JerseyHumana Independence Blue CrossIndependent HealthKaiser PermanenteL.A. Care Health PlanMolina HealthcareNeighborhood Health Plan of Rhode IslandPoint32HealthPremera Blue CrossRegence BlueShield, Regence BlueShield of Idaho, Regence BlueCross BlueShield of Oregon, Regence BlueCross BlueShield of Utah, Asuris Northwest Health, BridgeSpan HealthSCAN Health PlanSummaCareUnitedHealthcare Wellmark Blue Cross and Blue Shield Kidney dialysis industry accused of maximizing profits over patients Pentagon officials reveal new details about U.S. strikes on Iran's nuclear sites Netanyahu reacts to U.S. strikes on Iranian nuclear sites

Bloomberg

34 minutes ago

• Bloomberg

Medicaid Cuts Will Hurt Nearly Half of America's Kids

Republican lawmakers claim their proposal to cut hundreds of billions of dollars from Medicaid is designed to protect the country's most vulnerable — that by focusing on work requirements, they're simply eliminating waste from the bloated program and ensuring the money goes to those who truly need it. In reality, anyone who relies on public insurance could be affected, including about 37 million kids, nearly half of all American children.